Slingshot members are tracking this event:
Novartis' (NVS) PKC412 for Newly-Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Designated Breakthrough Therapy by FDA
Slingshot Insights Explained
Feb 19, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Pkc412, Newly-diagnosed, Flt3-mutated Acute Myeloid Leukemia, Fda, Breakthrough Therapy Designation